Singlera Genomics Partners with Pure Medical to Expand DNA Methylation Cancer Detection Technology Across Europe
Key Insights
Singlera Genomics (search) has signed a research and distribution agreement with Pure Medical (search) to bring its mTitan (search) and mGuard (search) cancer detection platforms to multiple European countries.
The platforms use DNA methylation (search) technology to screen circulating cell-free DNA for cancer signals, often detecting cancer before symptoms appear across six cancer types.
Pure Medical (search) will collaborate with universities, hospital networks, and healthcare systems across western Europe to commercialize the technology in seven EU countries.
Singlera Genomics (search) announced a strategic research and distribution agreement with European Union-based Pure Medical to expand access to its DNA methylation (search)-based cancer detection technology across western Europe. The partnership will focus on bringing Singlera's mTitan (search) and mGuard (search) platforms to multiple European markets, with particular emphasis on colorectal and pancreatic cancer (search) detection.
DNA Methylation Technology for Early Cancer Detection
Singlera's mTitan (search) and mGuard (search) platforms utilize proprietary DNA methylation (search) technology to screen circulating cell-free DNA for cancer-associated signals, often detecting malignancies before symptoms manifest. The patented technology has demonstrated capability in non-invasively detecting methylation haplotypes from six cancer types: esophageal, colorectal, gastric, lung, liver, and pancreatic cancers.
"We are excited to partner with Pure Medical (search) to focus on cancer detection and surveillance across western Europe, including colorectal and pancreatic cancer (search)," said Qiang Liu, COO and co-founder of Singlera Genomics (search). "This distribution agreement represents an important step in our European business strategy to bring inexpensive early cancer detection and monitoring to the global patient population; we hope that Singlera's methylation products can give clinicians an important tool for faster detection, diagnosis, and treatment of cancer."
European Market Expansion Strategy
Under the agreement terms, Singlera and Pure Medical (search) will collaborate with local universities, hospital networks, and national healthcare systems on research studies across western Europe. The partnership also encompasses commercial distribution of mTitan (search)- and mGuard (search)-based assays in several European countries.
Pure Medical (search) CEO Maarten van Dijk emphasized the company's existing infrastructure for technology adoption: "We are already engaged in research collaborations with academic and healthcare institutions across the UK and Europe, and are working toward the earliest possible commercialization of Singlera's colorectal and pancreatic cancer (search) products across seven EU countries."
Clinical Implementation and Healthcare Integration
The collaboration aims to translate innovative cancer detection technology into real-world clinical benefit through Pure Medical (search)'s established relationships with European healthcare systems. Van Dijk noted that the "innovative, non-invasive technologies have the potential to support earlier detection and more effective monitoring of colorectal and pancreatic cancer (search)."
Pure Medical (search), founded in 2015, specializes in supporting the introduction and adoption of new medical technologies within national healthcare systems. The company works closely with innovative healthcare specialists, governments, and medical professionals to address current and future healthcare challenges.
Company Background and Technology Platform
Singlera Genomics (search), established in July 2014, operates as a global enterprise specializing in non-invasive genetic diagnosis with research and development centers and business operations worldwide. The company's proprietary technologies encompass single-cell sequencing, DNA methylation (search), and bioinformatics platforms.
The partnership represents Singlera's strategic expansion into European markets, leveraging Pure Medical (search)'s established network of academic and healthcare institutional collaborations to accelerate the clinical adoption of methylation-based cancer detection technology.